Advances in Antidiabetic Drugs Targeting Insulin Secretion

Author(s): Yanting Ding, Yilian Li, Qin Chen*, Bing Niu*

Journal Name: Current Pharmaceutical Design

Volume 24 , Issue 34 , 2018

Become EABM
Become Reviewer


Background: Diabetes mellitus (DM) is a disease of systemic metabolic disorders caused by the decrease of secretion or sensitivity of insulin. In recent years, the study of insulin-related drug targets and the development of new drugs have become the popular topic of current medical research, and studies have shown that multiple signaling pathways are associated with diabetes treatment. At present, some new drugs based on the new target design have been listed on the market and have achieved good hypoglycemic effect. However, most of the drugs are still in the clinical or pre-clinical stage. The efficacy and safety of the drugs need further clinical validation.

Objective: This article will introduce the advancements of targets and drugs to promote insulin secretion.

Keywords: Diabetes mellitus, antidiabetic drugs, GLP-1R, KATP, GPR119, insulin.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2018
Page: [3990 - 3997]
Pages: 8
DOI: 10.2174/1381612824666181112113756
Price: $65

Article Metrics

PDF: 31
PRC: 1